3 results
Approved WMOCompleted
To determine the safety and tolerability of P1201-07 administered as single ascending oral doses in overweight or obese but otherwise healthy subjects.
Approved WMORecruiting
Aim: To investigate the efficacy of nortriptyline in FD patients with a predicted CYP2D6 extensive metabolizer phenotype. Nortriptyline is a second generation TCA with significantly fewer anticholinergic side effects compared to the first generation…
Approved WMOCompleted
Primary objectiveThe primary objective of the study is to determine the effect of lucerastat on neuropathic pain in subjects with Fabry disease (FD).Secondary objectives* To determine the effects of lucerastat on gastro-intestinal (GI) symptoms (…